Explore the words cloud of the IF-EBOla project. It provides you a very rough idea of what is the project "IF-EBOla" about.
The following table provides information about the project.
Coordinator |
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Organization address contact info |
Coordinator Country | France [FR] |
Project website | http://infightebola.eu/ |
Total cost | 2˙037˙770 € |
EC max contribution | 1˙992˙770 € (98%) |
Programme |
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being) |
Code Call | H2020-Adhoc-2014-20 |
Funding Scheme | RIA |
Starting year | 2014 |
Duration (year-month-day) | from 2014-11-01 to 2017-10-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT | FR (MARSEILLE) | coordinator | 360˙895.00 |
2 | FABENTECH | FR (LYON) | participant | 972˙750.00 |
3 | BEN-GURION UNIVERSITY OF THE NEGEV | IL (BEER SHEVA) | participant | 199˙350.00 |
4 | ORION INTEGRATED BIOSCIENCES INC. | US (NEW ROCHELLE) | participant | 135˙000.00 |
5 | INSTITUT PASTEUR | FR (PARIS CEDEX 15) | participant | 127˙075.00 |
6 | METABIOTA INC | US (SAN FRANCISCO) | participant | 100˙000.00 |
7 | ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO | IT (ROMA) | participant | 52˙700.00 |
8 | ABSISKEY | FR (ANGERS) | participant | 45˙000.00 |
9 | ABSISKEY CP | FR (GRENOBLE) | participant | 0.00 |
10 | UNIVERSITY OF MANITOBA | CA (MANITOBA) | participant | 0.00 |
IF-EBOLA has been strategically designed to efficiently respond to critical needs required to control Ebola outbreak from spreading and prepare a therapeutic approach to save lives. The work involves two of the main EVD outbreak sites, Sierra Leone and Liberia. MDs, public health authorities and virus experts working on site, under ethical regulatory rules, will extend their collaboration to companies and institutions to form a consortium of outstanding complementary partners, sharing their innovative technological approaches for a common goal. The main goal of our project is to contribute to provide innovative ultrasensitive diagnostics and therapeutic approaches for an early and accurate diagnostic for an early therapeutic treatment to control the epidemic and safe lives.
We have been obligated to modify and extend for one year our initial two-year period IF-EBOLA action program due to both major foreseen and unforeseen changes produced during this “non-emergency” period: consisting mainly now in 3 main actions: (i) Preclinical validation of the therapeutic equine anti-Ebola antibodies; (ii) Clinical validation of the ultrasensitive detection (iii) homeostasis (“pathology”) profiling of patients and survivors. Originally (“emergency period”) IF-EBOLA included 2 phases: (I) a phase of preparation including, ethical authorizations, antibody production, technical and field organization as well as the beginning a follow-up of the homeostatic profile of contacts early-EBOV diagnosed and self-cured convalescent individuals in the absence of existing treatment, (with an ultrasensitive detection method of pernicious microorganisms, from the EC USDEP project qualified as a European success story “USDEP” project in 2010 by the EC-Project Officer) and (II) phase of a clinical study using a wide validated approach revisited with an innovative concept (strongly supported EC/EMA-WHO), we propose to carry out an experimental passive-immune therapy based on neutralizing capacity of horse anti-EBOV polyclonal F(ab’)2 on early-diagnosed patients to impact and reduce their pre-existing viremia, their mortality, the evolution of their homeostasis profile, during and after this treatment (once patients become convalescents). The homeostasis status evolution will help to generate high quality scientific data to understand the EVD, the effect of this therapy and cure parameters characterized at 3 different levels: immune (transcriptomes, NGS, metagenomics); infectious (other than EBOV, DNA arrays), and EBOV diversity (sequencing and metagenomics).
Whole infectious profiles | Documents, reports | 2019-10-29 14:07:31 |
Ebola virus diversity assessed by sequencing | Documents, reports | 2019-10-28 17:21:42 |
Ethical regulations, security and safety set up for diagnostic and follow-up of patients of the phase 1 (without treatment) | Documents, reports | 2019-10-28 17:21:42 |
Creation of the specific website of the project | Websites, patent fillings, videos etc. | 2019-10-28 17:21:42 |
Take a look to the deliverables list in detail: detailed list of IF-EBOla deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2015 |
W. Valdivia, D. Sheoran, & F. Veas Ebola virus Genomic and Metagenomic signature Analyses of the 2014-15 West African Outbreak published pages: , ISSN: , DOI: |
7th Filovirus Conference | 2019-10-28 |
2017 |
Aly Shamseddin, Céline Crauste, Erwann Durand, Pierre Villeneuve, Gregor Dubois, Thierry Durand, Joseph Vercauteren, Francisco Veas Resveratrol formulated with a natural deep eutectic solvent inhibits active matrix metalloprotease-9 in hormetic conditions published pages: 1700171, ISSN: 1438-7697, DOI: 10.1002/ejlt.201700171 |
European Journal of Lipid Science and Technology 119/11 | 2019-10-28 |
2017 |
F.Veas Efficiency of innovative preparedness IF-EBOLA technologies: Ultrasensitive diagnostics, horse anti-Ebola virus polyclonal Fabs & metagenomic analyses of Ebola variants and co-infections published pages: , ISSN: , DOI: |
2019-10-28 | |
2017 |
Y. Eskira A Sobarzo, F Veas L Lobel Atypical immune response of EVD Long-term survivors published pages: , ISSN: , DOI: |
2019-10-28 | |
2015 |
W. Valdivia-, D. Sheoran, G. Dubois, S. Tigrett, F. Veas Metagenomic analyses and genomic fingerprint of co-infections of the EBOLA viral disease published pages: , ISSN: , DOI: |
2019-10-28 | |
2015 |
C. Herbreteau & IF Ebola Development of a specific polyclonal immunoglobulin against Ebola published pages: , ISSN: , DOI: |
2019-10-28 | |
2015 |
F.Veas Multi-technological platforms to solve unmet needs for rapid and efficient management of emerging diseases published pages: , ISSN: , DOI: |
2019-10-28 | |
2017 |
M. Denizot, T. Racine, D. Pannetier, A. Pasquier, H. Raoul, JF Saluzzo, G. Kobinger, F. Veas, C. Herbreteau Specific polyclonal F(ab’)2immunoglobulin fragments; in vitro characterization and in vivo effectiveness in post-exposure treatment against Zaire Ebola virus in mice published pages: , ISSN: , DOI: |
2019-10-28 | |
2018 |
A Shamseddin, C Crauste, E Durand, P Villeneuve, G Dubois, T Pavlickova, Th Durand, J. Vercauteren, and F Veas Resveratrol-Linoleate protects from exacerbated endothelial permeability via a drastic inhibition of the MMP-9 activity published pages: , ISSN: , DOI: |
2019-10-28 | |
2017 |
R Metrop, JF Saluzzo, F Veas, C. Herbreteau Lessons Learned from the Development of an Ebola Immunotherapy published pages: , ISSN: , DOI: |
2019-10-28 | |
2017 |
S Tigrett, L Lobel, F Veas A Universal virus capture method leading to a rapid and ultrasensitive detection of pathogens for early & late post-exposure countermeasures published pages: , ISSN: , DOI: |
2019-10-28 | |
2015 |
W. Valdivia, D. Sheoran & F. Veas RIGEL as a Powerful Computational Architecture for Genomic & Metagenomic Signature Discrimination: Analysis of the 2014-15 West African EBOLA Outbreak†published pages: March 8-13, 2015, ISSN: , DOI: |
Gordon Research Conferences, on | 2019-10-28 |
2016 |
F.Veas The preparedness IF-EBOLA toolbox for rapid and efficient mitigation of upcoming outbreaks. A platform model for emerging diseases published pages: , ISSN: , DOI: |
2019-10-28 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IF-EBOLA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IF-EBOLA" are provided by the European Opendata Portal: CORDIS opendata.